MEETING CURRENT AND FUTURE SERIALISATIONCHALLENGES

whitePaper | November 3, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result of a collaborative process facilitated and endorsed by the World Economic.

whitePaper | July 11, 2022

The expansion in the development and manufacturing of highly potent active pharmaceutical ingredients (HPAPIs) and complex active pharmaceutical ingredients (APIs) has grown tremendously as demands in healthcare to bring newer therapies to market quicker increase.

whitePaper | February 3, 2023

Since the beginning of the COVID-19 pandemic, pharmaceutical organizations have experienced major changes, a prime example of which has been the rising requirement for collaborations on multiple different fronts across the industry.

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.

whitePaper | February 5, 2022

Essential medicine access is one of the main objectives of healthcare systems in and pharmaceutical supply chains ensure that the right amount of medicine, with acceptable quality, will reach the customers in need